Developing specific MCL‐1 inhibitors and dual inhibitors that target multiple antiapoptotic proteins simultaneously can further overcome resistance by preventing cancer cells from compensating through alternative pathways.225, 226, 227. The gene discussed is MCL1; the disease is cancer.